These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7737222)

  • 21. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Comparison of the lowering effect on blood cholesterol of clofibrate and simvastatin].
    Gavelli MS; Vitaliano E; Serra T; Rossi FG; Rizzuti A; Caridis R; Tozzi J
    Clin Ter; 1990 May; 133(3):145-50. PubMed ID: 2142901
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-benefit analysis of lipid lowering therapy.
    Davie AP; McMurray JJ
    Eur Heart J; 1996 Jul; 17(7):974-5. PubMed ID: 8809507
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatment of lipids. Implications for the general practitioner.
    Simons LA
    Aust Fam Physician; 1996 Jul; 25(7):1053-9. PubMed ID: 8768271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simvastatin in the media.
    Watt G; Galbraith W
    N Z Med J; 1989 Dec; 102(881):651-2. PubMed ID: 2608245
    [No Abstract]   [Full Text] [Related]  

  • 26. Improved survival with statin therapy.
    Clem JR
    S D J Med; 1996 Aug; 49(8):273-4. PubMed ID: 8803474
    [No Abstract]   [Full Text] [Related]  

  • 27. [Treatment of dyslipidemia of the elderly with simvastatin and pravastatin. Effectiveness and tolerance].
    Panuccio D; Trabatti MR; Romani A
    Clin Ter; 1994 May; 144(5):419-24. PubMed ID: 7924180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of diagnostic cluster methodology for therapeutic costing and drug surveillance of HMG-CoA reductase-inhibitor therapy.
    Bottorff MB; Yenkowsky JP; Cave DG
    Clin Ther; 1999 Jan; 21(1):218-35. PubMed ID: 10090437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia.
    Hoogerbrugge N; Jansen H; De Heide L; Zillikens MC; Deckers JW; Birkenhäger JC
    J Intern Med; 1997 Feb; 241(2):151-5. PubMed ID: 9077372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal.
    Pedersen TR; Tobert JA
    Drug Saf; 1996 Jan; 14(1):11-24. PubMed ID: 8713485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical implications of new drugs for lowering plasma cholesterol concentrations.
    Illingworth DR
    Drugs; 1991 Feb; 41(2):151-60. PubMed ID: 1709846
    [No Abstract]   [Full Text] [Related]  

  • 32. HMG CoA reductase inhibitors as lipid-lowering agents: five years experience with lovastatin and an appraisal of simvastatin and pravastatin.
    Maher VM; Thompson GR
    Q J Med; 1990 Feb; 74(274):165-75. PubMed ID: 2111917
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
    Kłosiewicz-Latoszek L; Respondek W; Białobrzeska-Paluszkiewicz J; Grzybowska B; Jakóbisiak-Ostasz B; Stolarska I
    Pol Merkur Lekarski; 2003 Jul; 15(85):42-6. PubMed ID: 14593958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Hyperlipidemia and arteriosclerosis].
    Mabuchi H
    Nihon Naika Gakkai Zasshi; 1998 May; 87(5):950-7. PubMed ID: 9648450
    [No Abstract]   [Full Text] [Related]  

  • 35. Smoking diminishes the beneficial effect of statins: observations from the landmark trials.
    Milionis HJ; Rizos E; Mikhailidis DP
    Angiology; 2001 Sep; 52(9):575-87. PubMed ID: 11570656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatin.
    Gotto AM
    Am J Cardiol; 2005 Sep; 96(5A):34F-38F. PubMed ID: 16126021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients.
    Strony J; Hoffman R; Hanson M; Veltri E
    Clin Ther; 2008 Dec; 30(12):2280-97. PubMed ID: 19167588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simvastatin versus pravastatin: efficacy and tolerability in patients with primary hypercholesterolemia.
    Malini PL; Ambrosioni E; De Divitiis O; Di Somma S; Rosiello G; Trimarco B
    Clin Ther; 1991; 13(4):500-10. PubMed ID: 1934003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Implications of 4S evidence on baseline lipid levels.
    Jacobson TA
    Lancet; 1995 Jul; 346(8968):181-2. PubMed ID: 7603245
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.